Sesen hit with surprise FDA CRL for Vicineum in NMIBC

In terms of efficacy, the gene therapy has provided some compelling data. In Fergene's phase III study, 53% of patients achieved a CR at three months, ...
https://www.google.com/url?rct=j&sa=t&url=https://www.bioworld.com/articles/510433-sesen-hit-with-surprise-fda-crl-for-vicineum-in-nmibc&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNFVrPbuKx6Yxf7URvcwGzGAbymeew